Piers A. Blombery

305 Grattan Street
Melbourne, VIC 3000, Australia

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 179 publications

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

CRISPR in clinical oncology: translational advances from molecular diagnostics to therapeutics.

Journal: Nature reviews. Clinical oncology

Published: June 10, 2026

T-ALL: the origin story.

T-ALL: the origin story.

Journal: Blood

Published: June 04, 2026

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

A quantitative definition of the clinical manifestations of GATA2 deficiency in adults.

Journal: Blood

Published: May 18, 2026

Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.

Long-term outcomes with continuous venetoclax for relapsed chronic lymphocytic leukemia.

Journal: Blood advances

Published: April 17, 2026

MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

MAP3K14 (NIK) synonymous variants drive altered splicing to activate NF-κB in mature B-cell malignancies.

Journal: Blood

Published: March 25, 2026

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

CAR transgenic T-cell lymphoproliferative neoplasm (CTTLN): malignant transformation of cellular immunotherapy.

Journal: Blood

Published: March 19, 2026

HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.

HAT-PCR is non-inferior to NGS when quantifying measurable residual disease for myeloma.

Journal: British journal of haematology

Published: February 12, 2026

A Case of Primary Cutaneous BRAFV600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA.

A Case of Primary Cutaneous BRAFV600E+ Langerhans Cell Histiocytosis, With Underlying Chronic Myelomonocytic Leukaemia, Responsive to Dabrafenib With Subsequent Undetectable Circulating Cell Free DNA.

Journal: The Australasian journal of dermatology

Published: February 09, 2026

KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia.

KRAS internal tandem duplications and alternative driver variants in BRAF Val600Glu negative hairy cell leukemia.

Journal: Leukemia & lymphoma

Published: January 13, 2026

Activating somatic EPOR mutation in primary erythrocytosis.

Activating somatic EPOR mutation in primary erythrocytosis.

Journal: Pathology

Published: December 22, 2025

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Obinutuzumab, lenalidomide, and venetoclax for the initial treatment of patients with advanced-stage follicular lymphoma: Results of the Phase Ib/II LEVERAGE study.

Journal: HemaSphere

Published: December 17, 2025

Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression.

Breast implant associated anaplastic large cell lymphoma is a heterogeneous T cell disease with active pro-tumour cross-talk and immune suppression.

Journal: Leukemia

Published: December 12, 2025

Showing 1-12 of 179

Last Updated: 09/26/2026